Trends and disparity in the provision and consumption of essential medicines in China from 2016 to 2021: institutional, regional, and economic variations
Mingyue Zhao, Chenglong Lin, Shengjie Ding, Yubei Han, Yuhan Zhao, Ali Hassen Gillani, Yu Fang

TL;DR
This study examines how essential medicines are provided and used in China from 2016 to 2021, finding significant differences based on region and economic development.
Contribution
The study reveals institutional, regional, and economic disparities in essential medicine provision and consumption in China.
Findings
The average number of essential medicines provided is much lower than the national list.
Essential medicine provision and consumption show significant institutional and regional disparities.
Highly developed regions have the highest supply but lowest utilization of essential medicines.
Abstract
Analyze the provision and consumption of essential medicines (EMs) across healthcare institutions, regions, and levels of economic development. Evaluate the mechanisms by which EMs policies promote their own implementation. Using national drug utilization monitoring database (2016–2021), we perform a descriptive analysis to explore trends and disparities in EM provision and consumption across three institution levels, four regions (from 30 provinces), and different economic development levels in China. Key metrics include the average number and proportion of provided EMs and the consumption rate per healthcare institution. Utilize a two-way fixed-effects regression model to evaluate the relationship between EMs provision and consumption. The average provided number of EMs is much lower than that in the national EMs list. Both provision (number and proportion) and consumption of EMs…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Economics and Policy · Healthcare Systems and Reforms · Health Systems, Economic Evaluations, Quality of Life
